Search form
Search
Login
Subscribe
Home
Country Intelligence
Industry Directory
Offsets / IC
Tenders
Australia
(15/week)
Haiti
(0/week)
Guyana
(0/week)
Honduras
(0/week)
Guatemala
(0/week)
View all
(15/week)
News
United States
(643/week)
Manufacturing
(442/week)
Energy
(369/week)
Technology
(457/week)
Other Manufacturing
(373/week)
Events
About us
Who we are
Our People
Partners
Contact us
LinkedIn
Login
Twitter
Register
Home
News
Crizanlizumab
Nov 18, 2019
New Sickle Cell Drug With Oklahoma Roots Receives FDA Approval
Nov 15, 2019
New Novartis medicine Adakveo® (crizanlizumab-tmca) approved by FDA to reduce frequency of pain crises in individuals living with sickle cell disease
Nov 15, 2019
FDA approves first targeted therapy to treat patients with painful complication of sickle cell disease
Nov 04, 2019
Sickle Cell Disease Market Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis by DelveInsight
Jan 08, 2019
Novartis investigational therapy crizanlizumab (SEG101) receives FDA Breakthrough Therapy designation for the prevention of vaso-occlusive crises in sickle cell disease
Dec 01, 2018
Novartis announces new crizanlizumab (SEG101) data analysis in sickle cell disease, and investment in SENTRY clinical program
Nov 28, 2018
Hillhurst Biopharmaceuticals Receives Phase 2 SBIR Funding For Clinical Development Of HBI-002 For Prevention Of Vaso-Occlusive Crises in Sickle Cell Disease
Oct 09, 2018
Novartis analysis shows crizanlizumab (SEG101) increased the number of patients free of sickle cell pain crises vs placebo during SUSTAIN study
May 23, 2018
Sickle Cell Anemia: Global Drug Market Outlook to 2024 - A $350 Million Market Opportunity
Dec 13, 2017
Prolong Pharmaceuticals Announces Completion of Enrollment in Phase II Study of SANGUINATE® in the Treatment of Sickle Cell Disease Patients with Vaso-Occlusive Crisis in an Ambulatory Setting
Dec 11, 2017
Novartis drug crizanlizumab shown to prolong time to patients' first sickle cell pain crisis in subgroup analysis of SUSTAIN study
Latest News
May 9, 2024
Hess Midstream Operations LP Announces Pricing of Upsized Private Offering of Senior Notes Due 2029
May 9, 2024
Altius Reports Q1 2024 Attributable Royalty Revenue of $17.4M and Adjusted Earnings(1) of $3.5M
May 9, 2024
SunOpta Announces First Quarter Fiscal 2024 Financial Results
May 9, 2024
Atmos Energy Corporation Reports Earnings for Fiscal 2024 Second Quarter; Raises Fiscal 2024 Guidance
May 9, 2024
Atmos Energy Declares Regular Quarterly Dividend
May 9, 2024
Redwire Corporation Reports First Quarter 2024 Financial Results
May 9, 2024
The Toro Company to Announce Fiscal 2024 Second Quarter Results
May 9, 2024
Excelerate Energy Reports Strong First Quarter 2024 Results
View all News
Agenda
29
October
United Kingdom
Copthorne Tara Hotel, London, UK
International Dismounted Soldier, 29-30 October 2024, Copthorne Tara Hotel, London, UK
Navigating the Evolving Battlespace: Enhancing the Capabilities of the Dismounted Soldier The modern battlefield...
24
September
United Kingdom
Hilton London Syon Park, London, UK
Defence Transformation Conference, 24-26 September 2024, Hilton London Syon Park, London, UK
Returning for its 8th year, Defence Transformation 2024 will feature an updated format that will address all aspects of...
17
June
France
Parc des Expositions de Paris Nord Villepinte ZAC Paris Nord 2, 93420 Villepinte – France (Halls 5a – 5b – 6)
Eurosatory 2024, 17 - 21 June 2024, Parc des Expositions de Paris Nord Villepinte ZAC Paris Nord 2, 93420 Villepinte – France (Halls 5a – 5b – 6)
Eurosatory 2024 There can be no sustainable world without peace and security. Founded in 1967, the exhibition...
View All Events